Page 392 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
Watchful Waiting Age <85 yr, PSA every 3 mo. Developing progressive NR
Study, US 147 biopsy proven disease or electing to
[14501381] prostate cancer initiate cancer therapy
within 48 mo,
1998-2003 PSA <50
ng/mL, have not
received any
therapy
including
surgery,
radiation,
hormone or
chemotherapy,
have not been
diagnosed with
metastatic
disease, at
least 3-yr life
expectancy, no
history of any
type of
malignancy
within the past
5 yr with the
exception of
non-melanoma
skin cancer,
liver and kidney
function within
1.5 x upper
range of
normal, not
taking > 50 ug
selenium/day
as supplement,
Gleason score
<8.

C-114